Latest Judah Folkman Stories
SALT LAKE CITY, July 16, 2012 /PRNewswire/ -- Most people know good leadership when they see it, and the newest book from Jack Zenger and Joseph Folkman of leadership development firm Zenger Folkman gives data-backed best practices that, if followed, give leaders and organizations a distinct advantage that is actually demonstrable and measurable in terms of all the measurements that define success: employee engagement, employee loyalty, and revenue results. - To download a free...
CAMBRIDGE, Mass., April 26, 2012 /PRNewswire/ -- The Angiogenesis Foundation has opened registration for its 10th Annual M. Judah Folkman International Conference--Antiangiogenesis: New Frontiers in Therapeutic Development. The conference will take place on October 6-7, 2012 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific and clinical findings on antiangiogenic cancer therapies. The M. Judah Folkman...
Ability to culture rare tumor cells isolated from blood could help improve patient response to therapy A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children’s Hospital Boston has created a microfluidic device that can harvest rare circulating tumor cells (CTCs) from blood to enable their expansion in culture for analysis. These cells, which have detached from a primary cancer site and often create a secondary -- or...
AUSTIN, Texas, March 5, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Platelet biomarkers for cancer." The patent resulted from a collaboration with the late Dr. Judah Folkman, a renowned cancer expert, and identifies three biomarkers that can be used to assess changes in endogenous angiogenesis in a subject. Angiogenesis is commonly...
See 17 TED MED-style talks on Children's Hospital Boston's latest devices, technologies, and clinical innovations BOSTON, Feb. 2, 2012 /PRNewswire-USNewswire/ -- On February 14 from 1 to 5 p.m., Children's Hospital Boston, will hosts its first "Innovation Day." In a series of 17 short sessions, cutting-edge approaches to improving care delivery and quality while lowering costs will be presented by the innovative leaders at Children's Hospital Boston. The event is sponsored by the...
CAMBRIDGE, Mass., Sept. 23, 2011 /PRNewswire/ -- Efficacy and safety data from VELOUR, the pivotal Phase III trial of aflibercept (VEGF Trap, ZALTRAP(TM)) for the treatment of metastatic colorectal cancer (mCRC) will be presented by Edith P. Mitchell, M.D., a leading cancer researcher, at the Angiogenesis Foundation's 9th Annual M. Judah Folkman International Conference: Antiangiogenesis: New Frontiers in Therapeutic Development on October 29-30, 2011 at the Hyatt Regency Cambridge. The...
CAMBRIDGE, Mass., Aug. 18, 2011 /PRNewswire/ -- Leading angiogenesis and cancer researcher Dr. Robert S. Kerbel of the University of Toronto will deliver the Future of Medicine Keynote Address at the Angiogenesis Foundation's 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development. The conference will take place on October 29-30, 2011 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific...
CAMBRIDGE, Mass., May 11, 2011 /PRNewswire/ -- The Angiogenesis Foundation has opened early registration for its 2011 Antiangiogenesis Conference that will take place on October 29-30 in Cambridge, MA. The 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development attracts key opinion leaders from academia, industry, government, and patient advocacy to discuss the latest information about research and therapeutic development in antiangiogenic therapy for...
 To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.Scientists at the UNC Lineberger Comprehensive Cancer...
Research in mice and human stem cells suggests new therapeutic targetsMost cancers are rare in people with Down syndrome, whose overall cancer mortality is below 10 percent of that in the general population. Since they have an extra copy of chromosome 21, it's been proposed that people with Down syndrome may be getting an extra dose of one or more cancer-protective genes. The late cancer researcher Judah Folkman, MD, founder of the Vascular Biology Program at Children's Hospital Boston,...
